Díaz PH

Language: Spanish
References: 10
Page: 41-42
PDF size: 158.62 Kb.

Text Extraction

No abstract.

REFERENCES

1. Su, S., “Epidemiology, genetic recombination, and pathogenesis of coronaviruses”, Trends Microbiol, 2016, 24 (6): 490-502.

2. Organization W.H., Summary table of sars cases by country, November 1, 2002-August 7, 2003”, 2020. Disponible en: http://www.who.int/csr/sars/country/2003_08_15/en/.

3. Organization W.H, “Middle East respiratory syndrome coronavirus (mers-cov)”, 30 de enero de 2019. Disponible en: http://www.who.int/emergencies/mers-cov/en/.

4. Organization W.H., covid-19. Disponible en: https://www. who.int/emergencies/diseases/novel-coronavirus-2019/ events-as-they-happen

5. https://www.who.int/blueprint/priority-diseases/keyaction/ draft-landscape-COVID-19-candidate-vaccines-23- April-2020.pdf?ua=1.

6. https://clinicaltrials.gov/ct2/results?cond=COVID&Search.

7. https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20200423-sitrep-94-covid-19.

8. Fu, B., Xu, X. y Wei, H., “Why tocilizumab could be an effective treatment for severe covid-19?” J Transl Med, 2020, 18: 164.

9. Grein, J., Ohmagari, N., Shin, D., Díaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M.L., Lescure, F.-X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., Chen, D., Chihara, S., Cohen, S.H., Cunningham, J., D’Arminio Monforte, A., Ismail, S., Kato, H., Lapadula, G., L’Her, E., Maeno, T., Majumder, S., Massari, M., Mora-Rillo, M., Mutoh, Y., Nguyen, D., Verweij, E., Zoufaly, A., Osinusi, A.O., DeZure, A., Zhao, Y., Zhong, L., Chokkalingam, A., Elboudwarej, E., Telep, L., Timbs, L., Henne, I., Seller,s S., Cao, H., Tan, S.K., Winterbourne, L., Desai, P., Mera, R., Gaggar, A., Myers, R.P., Brainard, D.M., Childs, R. y Flanigan, T., “Compassionate use of remdesivir for patients with severe Covid-19”, N Engl J Med, 2020. 10 de abril. NEJMoa2007016. doi: 10.1056/NEJMoa2007016. Online ahead of print.

10. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D. y Wang, C., “A trial of lopinavirritonavir in adults hospitalized with severe Covid-19”, N Engl J Med, 18 de marzo de 2020. NEJMoa2001282. doi: 10.1056/NEJMoa2001282. Online ahead of print.